

# NUCLEAR MEDICINE

**REPORT & DIRECTORY**

EDITION 2020




Marketed Radiopharmaceuticals

Clinical Radiopharmaceuticals

Early Stage Radiopharmaceuticals

# Nuclear Medicine, Edition 2020

- The global market for nuclear medicine reached almost US\$ 6 billion in 2019, growing by ~8% from 2018
- The market is expected to reach US\$ 30 billion in 2030



# Nuclear Medicine, Edition 2020


---

- Nuclear medicine remains a niche market representing less than 1% of the global pharmaceutical industry, but new opportunities lie ahead, especially in radiotherapeutics
  - Over five new radiotherapeutics with a blockbuster potential (annual sales potential  $\geq$ US\$ 1 billion) to reach the market before 2025
- Radiotherapeutics represented 20% of the global nuclear medicine market in 2019 and are expected to reach ~70% by 2030
- New radiotheranostics under development might lead to much stronger market figures than expected in coming years

# Nuclear Medicine, Edition 2020

---

- Seven companies controlled 67% of the world nuclear medicine market in 2019, the remaining 33% of the market is shared by 77 companies and public institutions



# Nuclear Medicine, Edition 2020


---

- During 2019, over 100 radiopharmaceuticals were marketed around the World, but some were only available locally
- The top 5 radiopharmaceuticals accounted for 20% of the world market
- $^{99m}\text{Tc}$  based radiopharmaceuticals accounted for less than 50% of the world market (in US\$), radiotherapeutics accounted for 20%
- Innovative solutions and additional sources will also emerge to cover the need for  $^{99}\text{Mo}$
- $^{177}\text{Lu}$  became the radionuclide of choice for therapy and radiotherapeutics will develop in parallel to their equivalent  $^{68}\text{Ga}$ - or  $^{89}\text{Zr}$ -labeled tracers
- During the past six years, over US\$ 16 billion were invested in M&A transactions in the radiopharmaceutical industry

# Nuclear Medicine, Edition 2020

- Over 100 companies are currently developing one or more radiodiagnostic or radiotherapeutic from their own pipeline

*Radiotherapeutics  
under development*



© MEDraysintell 2020

xxxxxxx

xxxxxxx

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026




# Nuclear Medicine, Edition 2020

---

- Nuclear Medicine Report & Directory Edition 2020
  - A set of three reports (~2,900 pages)
  - 830 products extensively described with over 440 radiopharmaceuticals under clinical or preclinical/early stage development
  - 320 companies active in NM comprehensively profiled
  - 2,300 bibliographical references and their Web links
- This new edition will prove once again to be the best advising tool to recognize opportunities that exist not only in diagnostic radiopharmaceuticals, but also in the radiotherapeutic development pipelines. Numerous opportunities exist for larger groups or investors to finance such development, and/or to merge with some partners

# How to subscribe?

To obtain a detailed table of contents and sample pages, please send an e-mail with your contact details to Paul-Emmanuel Goethals at [peg@medraysintell.com](mailto:peg@medraysintell.com)





# About MEDraysintell





Experts with a combined century of experience in

- Nuclear Medicine
- Particle therapy
- Brachytherapy

MEDraysintell provides strategic intelligence for the radiation healthcare to help clients understand

- Markets
- Competitive environment
- Potential for M&A
- Technology development

The most comprehensive set of reports & directories with over 4,000 pages of unrivaled intelligence, covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment



# Contact

---

- MEDraysintell reports and directories can be customized to specific areas or modalities
  - Sample pages and complete table of contents are available upon request
  - MEDraysintell also welcomes your requests for specific intelligence needs
- 

**Paul-Emmanuel Goethals, MBA**  
Louvain-la-Neuve, Belgium  
[peg@medraysintell.com](mailto:peg@medraysintell.com)  
Phone: +32 491 080 968

**Dr. Richard Zimmermann, PhD**  
Lalaye, France  
[rz@medraysintell.com](mailto:rz@medraysintell.com)  
Phone: +33 6 82 80 06 00

**[www.medraysintell.com](http://www.medraysintell.com)**

# Disclaimer

---

This MEDraysintell presentation and information contained herein, coming from the report “Nuclear Medicine World Report & Directory, Edition 2020” is believed to be accurate at the time of publication; it has been gathered in good faith from several public sources, but the authors are not in a position to guarantee its accuracy. The authors do not accept any responsibility for the content of this report/presentation. Information contained herein may be of a speculative nature and must be used with careful consideration. The authors assume no liability for any loss or damage – including but not limited to lost time, lost money, lost profits, lost customers – that may result from any use of the information or actions taken based on any analyses, projections, discussions, recommendations, or conclusions of any kind presented in this report/presentation.